This is an automated archive.

The original was posted on /r/conspiracy by /u/spiritfracking on 2023-10-17 08:04:38+00:00.

World’s First Inhalable COVID-19 vaccine:

The CanSino inhalable COVID-19 vaccine was launched in China in August, 2022. It is the first inhalable COVID-19 vaccine to be approved for use in the world. The vaccine is a recombinant adenovirus vector vaccine, which means that it uses a harmless cold virus to deliver the SARS-CoV-2 spike protein to the body. The spike protein is the protein that the virus uses to enter cells, so by generating antibodies to the spike protein, the vaccine can help to protect people from getting infected with COVID-19.

The CanSino inhalable vaccine is administered through a small nebulizer device that the user breathes into. The vaccine is absorbed into the lungs, where it can generate a strong immune response. The vaccine has been shown to be safe and effective in clinical trials, and it is expected to be a valuable tool in the fight against COVID-19.

The launch of the CanSino inhalable vaccine is a significant milestone in the development of COVID-19 vaccines. It is the first inhalable COVID-19 vaccine to be approved for use in the world, and it is expected to be a valuable tool in the fight against COVID-19. The vaccine is easy to administer and is less likely to cause pain or injection-site reactions than traditional injectable vaccines. It is also expected to be more effective in protecting against the Omicron variant of COVID-19.

The launch of the CanSino inhalable vaccine is a positive step forward in the global effort to control the COVID-19 pandemic. It is hoped that the vaccine will be widely available soon and will help to protect people from COVID-19, especially in developing countries where access to traditional injectable vaccines is limited.

Identified Side Effects (So-far…)

There is some evidence that the inhalable COVID-19 vaccine could lead to lung irritation in some people. In clinical trials, the most common side effects of the vaccine were mild and transient, and included cough, sore throat, and runny nose. These side effects were more common in people who received the vaccine for the first time, and were less common in people who received the vaccine as a booster dose.

In a small number of cases, people who received the inhalable vaccine reported more severe lung irritation, such as wheezing and chest tightness.

Here are some tips to help reduce the risk of lung irritation from the inhalable vaccine:

  • Take the vaccine in a well-ventilated area.
  • Avoid inhaling the vaccine too quickly.
  • Take deep breaths after inhaling the vaccine.
  • Drink plenty of fluids after inhaling the vaccine.
  • If you experience any lung irritation after inhaling the vaccine, such as cough, wheezing, or chest tightness, talk to your doctor.

Issues with Inhalable Vaccines Identified in the past

1960’s: Infants used as lab rats for bad RSV vaccine… Ended up spreading more RSV.

One example is the case of RespiGam, an inhalable RSV vaccine that was developed in the 1960s. RespiGam was tested in a clinical trial of over 15,000 infants, but the trial was stopped early after it was found that the vaccine was associated with an increased risk of hospitalization for pneumonia. RespiGam was never approved for use in the United States.

In these trials, infants were given a vaccine that was designed to protect them against respiratory syncytial virus (RSV). However, the vaccine actually made the infants more susceptible to RSV infection, and some of them died. This led to a moratorium on RSV vaccine development for several decades.

Another example is the case of Aerosolised Interferon Alpha, an inhalable interferon vaccine that was used to treat patients with hepatitis C in the 1980s and 1990s. Aerosolised Interferon Alpha was found to be effective in treating hepatitis C, but it was also associated with a number of side effects, including severe lung irritation. Aerosolised Interferon Alpha is no longer used to treat hepatitis C.

**2003-2016 "**FluMist vaccine" caused Guillain-Barré syndrome for over a decade

Another example is the case of FluMist vaccine. FluMist is an intranasal vaccine that was first approved for use in the United States in 2003. However, in 2016, the Centers for Disease Control and Prevention (CDC) recommended that FluMist not be used for the 2016-2017 flu season due to concerns about its effectiveness. The CDC found that FluMist was less effective than injectable flu vaccines at preventing influenza in children.

There have also been some reports of serious adverse events associated with inhalable vaccines. For example, in 2012, a study published in the journal Pediatrics reported that two children who received FluMist vaccine developed Guillain-Barré syndrome, a rare neurological disorder.

In 2016, a clinical trial of a new inhalable vaccine for respiratory syncytial virus (RSV) was halted after several participants developed serious side effects. The vaccine was designed to protect children against RSV, a common respiratory infection that can be serious, especially for infants. However, some of the participants in the trial developed inflammation in their lungs, and some required hospitalization.

And what is this? Could these vaccine trials have led to COVID-19?

In 2019, a mass-adoption of an inhalable influenza vaccine in Taiwan led to an outbreak of severe pneumonia. The 2019 inhalable influenza vaccine outbreak in Taiwan was a public health event that occurred after the mass-administration of a new type of influenza vaccine. The vaccine, which was administered through a nebulizer device, was designed to provide better protection against influenza than traditional injectable vaccines. However, after the vaccine was administered to over 1 million people in Taiwan, there was an increase in cases of severe pneumonia.

The outbreak began in November 2019, shortly after the start of the influenza season in Taiwan. The Taiwan Centers for Disease Control (TCDC) identified a cluster of cases of severe pneumonia in people who had recently received the inhalable influenza vaccine. The TCDC investigated the outbreak and found that the vaccine was associated with an increased risk of severe pneumonia.

The Taiwanese government investigated the outbreak and concluded that the vaccine was the likely cause. The vaccine was found to contain a high concentration of a substance called endotoxin, which can cause inflammation and pneumonia. The government also found that the vaccine was not manufactured in accordance with good manufacturing practices.

The Taiwanese government suspended the use of the vaccine and recalled all doses of the vaccine that had been distributed. The government also provided compensation to the victims of the vaccine-related pneumonia outbreak.

The TCDC suspended the use of the inhalable influenza vaccine in December 2019. By the end of the outbreak, there were over 400 cases of severe pneumonia and 36 deaths reported.